Clinical trials
Inflammatory Breast Cancer clinical trials
Below are recruiting inflammatory breast cancer clinical trials, each written for real people, not researchers. We’re tracking 332 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04744506Recruiting
Targeted removal of armpit nodes after chemotherapy for breast cancer
This trial studies a more targeted surgery to remove cancer-involved lymph nodes in the armpit after you finish chemotherapy before surgery. It may help doctors better remove affected nodes while avoiding unnecessary tissue removal.
Hangzhou, ZhejiangAges 18–85 - NCT07394387RecruitingPhase 2
HIFU with or without immunotherapy before chemo for triple-negative breast cancer
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
Nanjing, JiangsuAges 18–70 - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06879704Recruiting
Predicting breast cancer response to pre-surgery therapy with X-rays
This trial uses special imaging before and after treatment to see if it can predict how well triple-negative breast cancer responds to chemotherapy plus immunotherapy given before surgery. Participation could help doctors tailor future treatments.
RouenAges 18–75 - NCT05909332RecruitingPhase 3
Tested antivascular drug plus chemo versus chemo alone for TNBC
This Phase 3 trial compares an “anti-blood-vessel” drug added to chemotherapy versus chemotherapy alone for people with stage II–IIIC triple-negative breast cancer that has been completely removed with surgery. The goal is to see if adding the study drug improves outcomes after surgery (adjuvant treatment).
Beijing, Beijing MunicipalityAges 18–70 - NCT05866458Recruiting
Radiation after lumpectomy for node-negative breast cancer
This trial studies whether a specific radiation approach after lumpectomy can be helpful for certain people with early breast cancer that did not spread to lymph nodes at diagnosis. It focuses on people who finish neoadjuvant (before-surgery) treatment and reach a full response on final pathology.
Cudgen, CudgenAges 50 years+ - NCT07264985Recruiting
Gut bacteria and diarrhea in breast cancer patients on pyrotinib
This study looks at how gut bacteria relate to diarrhea in breast cancer patients who are taking a drug called pyrotinib. By understanding this link, doctors hope to better manage side effects in the future.
Wuhan, HubeiAges 18–75 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT06162559RecruitingPhase 1
Targeted therapy before surgery for HER2+ breast cancer
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
AmsterdamAges 18 years+ - NCT07658170Recruiting
Fat graft with platelet-rich fibrin for breast reconstruction after lumpectomy
This trial tests using a patient's own fat plus a special blood product (platelet-rich fibrin) to rebuild the breast right after a lumpectomy for breast cancer. It may help improve healing and appearance for women with early-stage, hormone-sensitive breast cancer.
Saint PetersburgAges 18–69 - NCT07581834RecruitingPhase 2
Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Fuzhou, FujianAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT07354919RecruitingPhase 2
Testing axelopran for advanced cancer patients on opioids
This trial tests if axelopran can help people with advanced prostate, breast, pancreatic, or lung cancer who are taking opioid pain medicines. It aims to see if the drug is safe and helps with bowel function.
Saint Louis Park, MinnesotaAges 18 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT04481932RecruitingPhase 2
Trastuzumab with chemo for HER2-positive breast cancer
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT05834764RecruitingPhase 2
Pyrotinib for high-risk HER2-positive early breast cancer
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Nanjing, JiangsuAges 18–75 - NCT05447702RecruitingPhase 2
Testes pre-surgery treatment for triple-negative breast cancer
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Chengdu, SichuanAges 18–75 - NCT05883852RecruitingPhase 3
HER2-positive breast cancer trial for women with lymph node spread
This Phase 3 trial compares two post-surgery drug plans for HER2-positive early breast cancer that has spread to nearby lymph nodes. It may help reduce cancer recurrence by testing which regimen works better after surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07695259RecruitingPhase 4
Olaparib with trastuzumab and pertuzumab for older women with HER2+ breast cancer
This study tests a combination of two antibody drugs (trastuzumab and pertuzumab) plus a targeted pill (olaparib) given before surgery to treat elderly women with HER2-positive breast cancer. The goal is to see if this approach helps shrink tumors or eliminate them entirely before surgery.
Hangzhou, ZhejiangAges 60 years+ - NCT07647263RecruitingPhase 2
New Drug Treatment Before Surgery for HER2-Positive Breast Cancer
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
Suzhou, JiangsuAges 18 years+ - NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT07616427RecruitingPhase 2
New drug plus hormone therapy for HER2-positive breast cancer
This study tests a new drug called fovinaciclib combined with hormone therapy and HER2-targeting drugs for early-stage breast cancer that has specific markers (HR-positive and HER2-positive). The goal is to shrink tumors before surgery and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07616453RecruitingPhase 2
New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hangzhou, ZhejiangAges 18–75
Hear when a new Inflammatory Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for inflammatory breast cancer?
- Yes. Clin2 currently lists 332 recruiting inflammatory breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a inflammatory breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a inflammatory breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.